AMRZ vs FNV

The company exhibits a Piotroski F-Score of 4/9, indicating stable but not robust financial health, while the absence of an Altman Z-Score limits distress risk assessment. Valuation metrics suggest the stock trades at a premium to both the Graham Number ($35.19) and intrinsic value ($16.52), supported by a high P/E of 22.98 versus sector peers. Despite solid operating margins and manageable leverage, earnings growth is negative year-over-year and quarterly earnings surprises have been inconsistent. Analysts recommend a 'buy' with a target price of $60.08, implying upside, but weak recent price performance and lack of dividend or insider activity temper near-term conviction.

Franco-Nevada exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a massive current ratio of 8.30, indicating a fortress balance sheet. While the stock trades at a significant premium to its Graham Number ($71.7) and Intrinsic Value ($170.21), this is supported by explosive YoY revenue growth of 85.8% and earnings growth of 108.8%. The company's royalty-based model is reflected in its extraordinary profit margins (61.64%), though current technical trends are bearish. Long-term value is driven by consistent earnings beats and a strong analyst target of $306.36. Price trades at a 28.6% premium to fair value estimate ($188.50), limiting near-term upside from a valuation perspective.